Skip to main content
Jinyu Bio-Technology Co.,Ltd. logo

Jinyu Bio-Technology Co.,Ltd. — Investor Relations & Filings

Ticker · 600201 ISIN · CNE000000Y37 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,777 across all filing types
Latest filing 2020-10-22 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 600201

About Jinyu Bio-Technology Co.,Ltd.

http://jinyubiotech.com/

Jinyu Bio-Technology Co., Ltd. focuses on the research, development, and manufacturing of veterinary biological products and pharmaceuticals. The company is a prominent supplier of animal vaccines, particularly specializing in Foot-and-Mouth Disease (FMD) vaccines, brucellosis vaccines, and solutions for swine and poultry diseases. It utilizes advanced biotechnology platforms, including large-scale suspension culture and high-efficiency purification processes, to produce high-titer, high-purity biologicals. The organization operates sophisticated research facilities and Biosafety Level 3 (P3) laboratories to support the development of diagnostic reagents and preventive treatments. Its operations center on enhancing animal health through scientific innovation, providing comprehensive disease control strategies for the global livestock industry and large-scale agricultural operations.

Recent filings

Filing Released Lang Actions
金宇生物技术股份有限公司关于聘任高级管理人员的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the appointment of a senior management person, specifically the hiring of a new Vice President and Chief Financial Officer. It includes details about the nomination, approval by the board, qualifications, and a brief resume of the appointee. There is no financial data, no report or presentation content, and it clearly relates to management changes. Therefore, it fits the category of Board/Management Information (MANG). The document length is short and focused solely on this announcement, confirming it is not a report or other filing type.
2020-10-22 Chinese
金宇生物技术股份有限公司2020年第三季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "2020 年第三季度报告" which translates to "2020 Third Quarter Report." It contains detailed financial data including balance sheets, profit and loss statements, cash flow analysis, and management commentary for the third quarter of 2020. The report is unaudited and covers a period shorter than a full fiscal year (specifically the first nine months and the third quarter). The presence of comprehensive financial statements and analysis for a quarterly period clearly identifies this as an Interim / Quarterly Report. The document length is substantial (15,000 characters), and it contains actual financial data, not just an announcement or certification. Therefore, the correct classification is Interim / Quarterly Report (IR). 9M 2020
2020-10-22 Chinese
关于子公司取得新兽药注册证书的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the approval of a new veterinary drug registration certificate for a subsidiary. It details the product, its registration, development background, and expected impact on the company. There is no financial data, no mention of financial results, no regulatory filings about board changes, no voting results, no merger or acquisition activity, and no report publication. The document is an official announcement about a regulatory approval related to product registration, which fits best under Regulatory Filings (RNS) as it does not fit other more specific categories.
2020-10-14 Chinese
关于使用闲置自有资金进行现金管理的进展公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from a company about its use of idle funds for cash management through entrusted financial products. It includes specifics about the entrusted financial products, contract terms, risk control measures, financial data, and independent director opinions. The document is not a financial report like an annual or interim report, nor is it a call transcript or management report. It is a regulatory announcement about capital management activities, specifically about the company's financing and investment activities with its own funds. This fits best under the category of Capital/Financing Update (CAP). The document length and detail confirm it is not a brief announcement or a simple report publication notice. Therefore, the classification is CAP with high confidence.
2020-10-08 Chinese
关于完成工商变更登记的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the completion of a business scope change registration with the local market supervision authority. It includes details about the updated business license information such as company name, legal representative, registered capital, and business scope. There is no financial data, no mention of financial results, no shareholder voting results, no executive changes, no legal proceedings, and no mention of any report publication. The document is a regulatory announcement about a corporate registration update, which fits best under Regulatory Filings (RNS) as it does not fit other specific categories.
2020-09-22 Chinese
2019年可持续发展报告
Regulatory Filings
2020-09-16 Chinese

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.